| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Acanthoside B targets multiple pathways involved in neuroprotection and inflammation. It inhibits acetylcholinesterase, reducing oxidative stress, and modulating inflammatory cytokines. It activates the TrkB/CREB/BDNF pathway, which is crucial for neuronal survival and synaptic plasticity. Its anti-inflammatory effects are mediated through the modulation of immune responses.
|
|---|---|
| ln Vitro |
In vitro, Acanthoside B has an inhibitory effect on allergic inflammation. It is a lignan with anti-inflammatory activity. Its ability to inhibit acetylcholinesterase has been demonstrated in biochemical assays. It also reduces the production of pro-inflammatory cytokines in cell culture models.
|
| ln Vivo |
When administered orally seven days before a Scopolamine injection, Acanthoside B (10–20 mg/kg) reduces the amnesic characteristics caused by Scopolamine in mice by regaining cholinergic activity, lowering endogenous antioxidant levels, reducing neuroinflammation, and stimulating the TrkB/CREB/BDNF pathway[1].
In vivo, Acanthoside B (oral gavage; 10-20 mg/kg; 7 days prior to Scopolamine injection) attenuates Scopolamine-inflicted AD-like amnesic traits in mice. It restores cholinergic activity, decreases endogenous antioxidant status, suppresses neuroinflammation, and activates the TrkB/CREB/BDNF pathway. These effects contribute to its anti-amnesic activity. |
| Enzyme Assay |
Non-cellular binding assays for Acanthoside B would involve measuring its binding affinity to acetylcholinesterase or its interaction with the TrkB receptor. These assays can be performed using surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC) with purified proteins. Its antioxidant activity can be assessed using cell-free assays such as DPPH radical scavenging.
|
| Cell Assay |
In vitro cellular assays for Acanthoside B are performed using neuronal cell lines or cells involved in inflammatory responses. The compound's ability to modulate inflammatory cytokine production or protect against neurotoxicity is assessed. Its effects on acetylcholinesterase activity can be measured in cell lysates.
|
| Animal Protocol |
Animal/Disease Models: Scopolamine-induced amnesic mouse model[1]
Doses: 10 mg/kg; 20 mg/kg Route of Administration: oral gavage; 7 days Experimental Results: demonstrated an anti-amnesic effect in mice. In vivo animal experiments for Acanthoside B are conducted in mouse models of Alzheimer's disease, such as the Scopolamine-induced amnesia model. The compound is administered via oral gavage at doses of 10-20 mg/kg for 7 days prior to Scopolamine injection. Behavioral tests, biochemical assays for cholinergic activity, and markers of oxidative stress and inflammation are evaluated. |
| ADME/Pharmacokinetics |
Acanthoside B has a molecular weight of 580.58 and a molecular formula of C28H36O13. Its CAS number is 7374-79-0. It is soluble in DMSO (50 mg/mL, 86.12 mM). For in vivo studies, it can be formulated in 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline. It is a solid and should be stored at -20°C.
|
| Toxicity/Toxicokinetics |
Toxicological data for Acanthoside B are not detailed in the search results. As a natural lignan, it is generally considered to have low toxicity. However, its safety profile would need to be fully characterized for any therapeutic development. It is intended for research use only.
|
| References |
|
| Additional Infomation |
(+)-Syringin β-D-glucoside is a β-D-glucoside with metabolic activity, and its function is related to (+)-syringin. It has been reported that styringin B has been found in Acanthus ilicifolius, Ligustrum obtusifolium, and other organisms with relevant data.
Acanthoside B is a lignan with anti-inflammatory and anti-amnesic effects. It can be used for Alzheimer's disease and lung inflammation research. It attenuates Scopolamine-inflicted AD-like amnesic traits by activating the TrkB/CREB/BDNF pathway. No clinical trial or regulatory approval information is available. |
| Molecular Formula |
C28H36O13
|
|---|---|
| Molecular Weight |
580.58
|
| Exact Mass |
580.215
|
| CAS # |
7374-79-0
|
| PubChem CID |
443024
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
778.5±60.0 °C at 760 mmHg
|
| Flash Point |
424.6±32.9 °C
|
| Vapour Pressure |
0.0±2.8 mmHg at 25°C
|
| Index of Refraction |
1.601
|
| LogP |
-1.6
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
41
|
| Complexity |
807
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
COC1=CC(=CC(=C1O)OC)[C@@H]2[C@H]3CO[C@@H]([C@H]3CO2)C4=CC(=C(C(=C4)OC)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)OC
|
| InChi Key |
WEKCEGQSIIQPAQ-IRBNZIFYSA-N
|
| InChi Code |
InChI=1S/C28H36O13/c1-34-16-5-12(6-17(35-2)21(16)30)25-14-10-39-26(15(14)11-38-25)13-7-18(36-3)27(19(8-13)37-4)41-28-24(33)23(32)22(31)20(9-29)40-28/h5-8,14-15,20,22-26,28-33H,9-11H2,1-4H3/t14-,15-,20+,22+,23-,24+,25+,26+,28-/m0/s1
|
| Chemical Name |
(2S,3R,4S,5S,6R)-2-[4-[(3S,3aR,6S,6aR)-3-(4-hydroxy-3,5-dimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-6-yl]-2,6-dimethoxyphenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (172.24 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.31 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.31 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.31 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7224 mL | 8.6121 mL | 17.2242 mL | |
| 5 mM | 0.3445 mL | 1.7224 mL | 3.4448 mL | |
| 10 mM | 0.1722 mL | 0.8612 mL | 1.7224 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
